ISEE - Iveric's Trial Progress And Other News: The Good Bad And Ugly Of Biopharma
Iveric Bio Goes Ahead with Second Pivotal Phase 3 Study of Zimura
Iveric Bio (ISEE) announced that it has dosed the first patients for its second pivotal Phase 3 clinical trial GATHER2. The study seeks to evaluate Zimura’s potential for treating patients with geographic atrophy secondary to age-related macular degeneration. The estimated primary completion date for the study is June, 2022.
GATHER2 trial is expected to recruit nearly 400 patients. These participants will be randomized to receive either monthly administration of Zimura 2 mg or sham during the first 12 months of the